NCT07185633 is a Phase 2 clinical trial of Gecacitinib-Corticosteroid in aGVHD, sponsored by Bin Gu.

Who is sponsoring NCT07185633?

NCT07185633 is sponsored by Bin Gu.

What drugs are being tested in NCT07185633?

Interventions in NCT07185633: Gecacitinib-Corticosteroid, Methylprednisolone sodium succinate.

Is NCT07185633 still recruiting?

NCT07185633 is currently not yet recruiting. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT07185633

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease

Not yet recruiting Phase 2 Last updated 22 September 2025

What this trial tests

Phase 2 trial testing Gecacitinib-Corticosteroid in aGVHD in 25 participants. Not yet recruiting.

Timeline

1 October 2025

Primary endpoint
1 October 2026

1 October 2027

Quick facts

Lead sponsor	Bin Gu
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 October 2025
Primary completion	1 October 2026
Estimated completion	1 October 2027

Drugs / interventions tested

Gecacitinib-Corticosteroid — full drug profile →
Methylprednisolone sodium succinate — full drug profile →

Conditions studied

aGVHD — all drugs for aGVHD →

Sponsor

Bin Gu — full company profile →

Who can join

18 and older, any sex, with aGVHD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial employs a single-arm, single-center design, planning to enroll 25 patients diagnosed with grade II-IV aGVHD at one center. Patients meeting all inclusion criteria and no exclusion criteria will be enrolled. After enrollment, all patients will receive Gecacitinib combined with methylprednisolone sodium succinate for at least 28 days. After 28 days of Gecacitinib treatment, patients evaluated by the investigator as achieving Complete Response (CR) or Partial Response (PR) may continue study treatment for up to 24 weeks. If patients experience intolerance, disease progression, or require new systemic therapy, treatment will be adjusted.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for aGVHD

Currently open trials in the same condition.

NCT07246031 — BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation · Phase 2 · recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07185633 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bin Gu
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07185633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing